Welcome to Medications.com

adams respiratory shares rise on outlook - Forbes

"management had initially assumed only $15 million of additional sales from the removal of competing products for mucinex d and dm, but based on product ...

http://www.forbes.com/feeds/ap/20... | Posted: Mon Oct 29 20:55:42 -0400 2007




© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea